The Pathogenesis of Focal Segmental Glomerulosclerosis

Advances in Chronic Kidney Disease

Volumn 21, Issue 5, 2014, Pages 408-416

  Jefferson, J Ashley ^a   Shankland, Stuart J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Focal segmental glomerulosclerosis; Glomerular disease; Parietal epithelial cell; Podocyte; Proteinuria

Indexed keywords

UROKINASE RECEPTOR;

GENETICS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLOMERULUS; HUMAN; MECHANICAL STRESS; METABOLISM; PATHOLOGY; PODOCYTE;

GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY GLOMERULUS; PODOCYTES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; STRESS, MECHANICAL;

EID: 84906724883     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.05.009     Document Type: Review

References (59)

1. D'Agati V.D., Fogo A.B., Bruijn J.A., et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004, 43:368-382.
2. Kriz W., Elger M., Nagata M., et al. The role of podocytes in the development of glomerular sclerosis. Kidney Int Suppl 1994, 45:S64-S72.
3. LeHir M., Kriz W. New insights into structural patterns encountered in glomerulosclerosis. Curr Opin Nephrol Hypertens 2007, 16:184-191.
4. Verani R.R., Hawkins E.P. Recurrent focal segmental glomerulosclerosis. A pathological study of the early lesion. Am J Nephrol 1986, 6:263-270.
5. Rood I.M., Deegens J.K., Wetzels J.F. Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice. Nephrol Dial Transplant 2012, 27:882-890.
6. Parsa A., Kao W.H., Xie D., et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013, 369:2183-2196.
7. Pollak M.R., Genovese G., Friedman D.J. APOL1 and kidney disease. Curr Opin Nephrol Hypertens 2012, 21:179-182.
8. McCarthy E.T., Sharma M., Savin V.J. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010, 5:2115-2121.
9. Wei C., Moller C.C., Altintas M.M., et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008, 14:55-63.
10. Wei C., El Hindi S., Li J., et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17:952-960.
11. Jefferson J.A., Alpers C.E. Glomerular disease: 'suPAR'-exciting times for FSGS. Nat Rev Nephrol 2013, 9:127-128.
12. Brenner B.M. Nephron adaptation to renal injury or ablation. Am J Physiol 1985, 249:F324-F337.
13. Kretzler M., Koeppen-Hagemann I., Kriz W. Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat. Virchows Arch 1994, 425:181-193.
14. Durvasula R.V., Petermann A.T., Hiromura K., et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004, 65:30-39.
15. Hoffmann S., Podlich D., Hahnel B., et al. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004, 15:1475-1487.
16. Matsusaka T., Asano T., Niimura F., et al. Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent. Hypertension 2010, 55:967-973.
17. Mulay S.R., Thomasova D., Ryu M., et al. Podocyte loss involves MDM2-driven mitotic catastrophe. J Pathol 2013, 230:322-335.
18. Fukuda A., Chowdhury M.A., Venkatareddy M.P., et al. Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol 2012, 23:1351-1363.
19. Zimanyi M.A., Hoy W.E., Douglas-Denton R.N., et al. Nephron number and individual glomerular volumes in male Caucasian and African American subjects. Nephrol Dial Transplant 2009, 24:2428-2433.
20. Wang L., Ellis M.J., Gomez J.A., et al. Mechanisms of the proteinuria induced by Rho GTPases. Kidney Int 2012, 81:1075-1085.
21. Akilesh S., Suleiman H., Yu H., et al. Arhgap24 inactivates Rac1 inmouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest 2011, 121:4127-4137.
22. Gee H.Y., Saisawat P., Ashraf S., et al. ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest 2013, 123:3243-3253.
23. Chang A.M., Ohse T., Krofft R.D., et al. Albumin-induced apoptosis ofglomerular parietal epithelial cells is modulated by extracellular signal-regulated kinase 1/2. Nephrol Dial Transplant 2012, 27:1330-1343.
24. Peired A., Angelotti M.L., Ronconi E., et al. Proteinuria impairs podocyte regeneration by sequestering retinoic Acid. J Am Soc Nephrol 2013, 24:1756-1768.
25. Shankland S.J. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006, 69:2131-2147.
26. Kriz W., Shirato I., Nagata M., et al. The podocyte's response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol 2013, 304:F333-F347.
27. Dandapani S.V., Sugimoto H., Matthews B.D., et al. Alpha-actinin-4 isrequired for normal podocyte adhesion. J Biol Chem 2007, 282:467-477.
28. Kim Y.H., Goyal M., Kurnit D., et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001, 60:957-968.
29. Wharram B.L., Goyal M., Wiggins J.E., et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005, 16:2941-2952.
30. Matsusaka T., Xin J., Niwa S., et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 2005, 16:1013-1023.
31. Matsusaka T., Sandgren E., Shintani A., et al. Podocyte injury damages other podocytes. J Am Soc Nephrol 2011, 22:1275-1285.
32. Fukuda A., Wickman L.T., Venkatareddy M.P., et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int 2012, 81:40-55.
33. Meyer T.W., Bennett P.H., Nelson R.G. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999, 42:1341-1344.
34. Steffes M.W., Schmidt D., McCrery R., et al. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int 2001, 59:2104-2113.
35. Benigni A., Morigi M., Rizzo P., et al. Inhibiting angiotensin-converting enzyme promotes renal repair by limiting progenitor cell proliferation and restoring the glomerular architecture. Am J Pathol 2011, 179:628-638.
36. Macconi D., Sangalli F., Bonomelli M., et al. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol 2009, 174:797-807.
37. Pichaiwong W., Hudkins K.L., Wietecha T., et al. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol 2013, 24:1088-1102.
38. Grahammer F., Wanner N., Huber T.B. Podocyte regeneration: who can become a podocyte?. Am J Pathol 2013, 183:333-335.
39. Meyer-Schwesinger C., Lange C., Brocker V., et al. Bone marrow-derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats. Am J Pathol 2011, 178:494-499.
40. Berger K., Schulte K., Boor P., et al. The regenerative potential of parietal epithelial cells in adult mice. J Am Soc Nephrol 2014, 25:693-705.
41. Pippin J.W., Sparks M.A., Glenn S.T., et al. Cells of renin lineage are progenitors of podocytes and parietal epithelial cells in experimental glomerular disease. Am J Pathol 2013, 183:542-557.
42. Shankland S.J., Anders H.J., Romagnani P. Glomerular parietal epithelial cells in kidney physiology, pathology, and repair. Curr Opin Nephrol Hypertens 2013, 22:302-309.
43. Ronconi E., Sagrinati C., Angelotti M.L., et al. Regeneration of glomerular podocytes by human renal progenitors. J Am Soc Nephrol 2009, 20:322-332.
44. Wanner N., Hartleben B., Herbach N., et al. Unraveling the role of podocyte turnover in glomerular aging and injury. J Am Soc Nephrol 2014, 25:707-716.
45. Appel D., Kershaw D.B., Smeets B., et al. Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 2009, 20:333-343.
46. Schulte K., Berger K., Boor P., et al. Origin of parietal podocytes in atubular glomeruli mapped by lineage tracing. J Am Soc Nephrol 2014, 25:129-141.
47. Sakamoto K., Ueno T., Kobayashi N., et al. The direction and role of phenotypic transition between podocytes and parietal epithelial cells in focal segmental glomerulosclerosis. Am J Physiol Renal Physiol 2014, 306:F98-F104.
48. Hackl M.J., Burford J.L., Villanueva K., et al. Tracking the fate of glomerular epithelial cells invivo using serial multiphoton imaging in new mouse models with fluorescent lineage tags. Nat Med 2013, 19:1661-1666.
49. Ohse T., Chang A.M., Pippin J.W., et al. A new function for parietal epithelial cells: a second glomerular barrier. Am J Physiol Renal Physiol 2009, 297:F1566-F1574.
50. Dijkman H., Smeets B., van der Laak J., et al. The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis. Kidney Int 2005, 68:1562-1572.
51. Ohtaka A., Ootaka T., Sato H., et al. Significance of early phenotypic change of glomerular podocytes detected by Pax2 in primary focal segmental glomerulosclerosis. Am J Kidney Dis 2002, 39:475-485.
52. Smeets B., Kuppe C., Sicking E.M., et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol 2011, 22:1262-1274.
53. Fatima H., Moeller M.J., Smeets B., et al. Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant. Clin J Am Soc Nephrol 2012, 7:1852-1858.
54. Smeets B., Uhlig S., Fuss A., et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol 2009, 20:2604-2615.
55. Kriz W., Hahnel B., Hosser H., et al. Pathways to recovery and loss ofnephrons in anti-Thy-1 nephritis. J Am Soc Nephrol 2003, 14:1904-1926.
56. Strassheim D., Renner B., Panzer S., et al. IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol 2013, 24:393-406.
57. Eremina V., Jefferson J.A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-1136.
58. Bock F., Shahzad K., Wang H., et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci U S A 2013, 110:648-653.
59. Isermann B., Vinnikov I.A., Madhusudhan T., et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007, 13:1349-1358.